Solid organ transplantation is the most effective treatment for end-stage organ failure, but the long-term outcomes remain suboptimal. CD4 þ regulatory T cells (Tregs) are emerging as a potential therapy to facilitate long-term allograft survival. This review provides a general overview of the biology of CD4 þ Tregs and then goes on to discuss the most relevant and recent experimental and clinical evidence for their therapeutic use in solid organ transplantation.
Introduction
Solid organ transplantation (SOT) is one of the major medical success stories of the past 50 years. Although short-term graft and patient survival rates posttransplantation have improved dramatically over recent times, this has not been mirrored by similarly improved 10-year and longterm outcomes [1] . For the majority of cases, the immunosuppressive regimens used to prevent organ rejection are culprit. These drugs are nonspecific, require lifelong use, favor the development of opportunistic infections and tumors, directly damage transplanted organs, and significantly increase cardiovascular morbidity and mortality [2, 3] . To address this, various therapies are being explored that may allow patients to retain a long-term functioning allograft under no immunosuppression or minimal immunosuppression (termed tolerance [4] and prope tolerance [5], respectively). Within this field, regulatory T cells (Tregs) have emerged as a promising candidate therapy [6] . Multiple heterogeneous populations of Treg exist, of which the CD4 þ population has attracted the most interest [7, 8] . This review will summarize the state-of-the-art of CD4 þ Treg therapy in SOT, discussing recent advances both experimentally and clinically.
Overview of regulatory T cells
Several regulatory mechanisms exist to avert excessive immune responses to pathogens and to prevent the development of autoimmune disease. CD4 þ Tregs (termed Tregs hereafter) are central to these mechanisms: mice lacking the Treg-specific transcription factor FoxP3 (scurfy mice) develop a lymphoproliferative disorder [9] , and humans with mutations in FoxP3 can develop IPEX (immunodysregulation, polyendocrinopathy and enteropathy, X-linked) syndrome [10] . FoxP3 is closely linked to suppressive activity and its sustained expression is required for the maintenance of regulatory activity [11] .
Tregs can be divided into thymic-derived naturally occurring CD4 þ CD25 hi Foxp3 þ Tregs (nTregs) [12] and induced or adaptive CD4 þ Tregs (iTregs), which upregulate FoxP3 in the periphery under conditions of antigen exposure and transforming growth factor-b (TGF-b) stimulation [13] [14] [15] . nTregs represent 5-10% of the peripheral CD4 þ pool and constitutively express high levels of surface CD25 (the a-chain of the interleukin (IL)-2 receptor), although this is not a reliable marker due to its upregulation on activated nonregulatory T cells. It is unclear how much of the peripheral CD4 þ population iTregs represent, but given that these cells are induced in specific inflammatory environments, it is likely that the percentage is location and time-dependent.
Other described regulatory CD4 þ T cells include Treg type 1 (Tr1) cells, which employ a FoxP3-independent suppression mechanism mediated via IL-10 and TGF-b [16] . Tr1 cells can be generated by stimulation with IL-10 or CD46 engagement and induce suppression by bystander regulation of effector T cells irrespective of their antigen specificity [16, 17] .
In humans, FoxP3 is upregulated on nonsuppressive recently activated CD4 þ T cells, making it a less useful marker than for mouse Tregs [18, 19] . Despite this, epigenetic studies have identified differences between the methylation status of the Treg-specific demethylated region (TSDR) site within the FoxP3 locus in different CD4 þ T cells. In naive and activated CD4 þ T cells, the TSDR is heavily methylated, whereas in iTregs, it is partially demethylated and in nTregs, it is completely demethylated [20, 21 ] . Analysis of Tregs based on quantitative methylation of the TSDR site is, therefore, a useful adjunct to the phenotyping of Tregs for clinical use [22] .
Differentiation of iTregs and nTregs may also be possible with the use of the transcription factor Helios, a member of the Ikaros transcription factor family. In a study by Thornton et al. [23 ] , Helios was found to be expressed on all thymically derived FoxP3 þ cells, but not on iTregs. Interestingly, 70% of peripheral Tregs in this study were Helios-positive, indicating that up to 30% of Tregs in the periphery may be iTregs.
Both nTregs and iTregs require T-cell receptor (TCR) engagement for activation and induction of suppression in vivo. Once activated, Tregs suppress immune responses at multiple levels by directly inhibiting both CD4 þ and CD8 þ T-cell activation and proliferation, as well as by preventing T-cell activation through modulation of antigen-presenting cell (APC) function [24] . Other described targets of Tregs include B cells, natural killer (NK) cells, natural killer T (NKT) cells, and mast cells [24] [25] [26] [27] . The molecular mechanisms involved in Treg suppressive activity are summarized in Fig. 1 [14, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] .
Treg suppressive activity may be inhibited by ligation of the glucocorticoid-induced tumor necrosis factor (TNF) receptor (GITR) on the surface of Treg [42] . Another member of the TNF receptor superfamily, OX40 (CD134), which is constitutively expressed on the surface of Tregs, appears to have a more complex role. OX40 Immature DC Regulatory T cells (Tregs) employ a multitude of redundant mechanisms to suppress immune responses [28] .
(1) Tregs can cause direct cytolysis of target cells through perforin-dependent and perforin-independent granzyme B mechanisms [29, 30] .
(2) Galectin-1 expressed on the surface of Tregs can bind target cells to induce cell cycle arrest and apoptosis [31] .
(3) Suppressive secreted cytokines such as interleukin (IL)-10, transforming growth factor-b (TGF-b), and IL-35 can induce bystander regulation of T cells [14, [32] [33] [34] . (4) Tregs inhibit the induction of IL-2 mRNA in target T cells [35] . (5) Surface CD25 on Tregs consumes IL-2 in the surrounding environment, depriving cells of this growth factor [36] . (6) Cytotoxic T lymphocyte antigen 4 (CTLA-4, CD152) interacts with CD80/CD86 on the surface of antigen-presenting cells (APCs) to prevent their binding to CD28, therefore indirectly inhibiting the activation of T cells [14, 37] . (7) The interaction of CTLA-4 and CD80/86 induces the expression of indoleamine 2,3-dioxygenase (IDO) from dendritic cells, which inhibits T-cell activation by depleting tryptophan from the extracellular milieu [38] . (8) Lymphocyte-activation gene 3 (Lag, CD223) on the surface of Tregs binds MHC class II to inhibit dendritic cell maturation [39] . (9) Fibrinogen-like protein 2 (FGL2) on the surface of Tregs binds FcgRIIB on the surface of dendritic cells to prevent their maturation [40] . (10) CD39 on the surface of Tregs hydrolyzes adenosine triphosphate (ATP) to adenosine monophosphate (AMP), reducing the availability of ATP-triggered proinflammatory signals [41] . DC, dendritic cell.
stimulation has been shown to reduce FoxP3 expression and Treg-mediated antitumor suppressive activity in vivo [43] . Furthermore, OX40-OX40 ligand interaction between Tregs and mast cells is important for suppression of degranulation and allergic responses [44] . However, in the additional presence of IL-6, mast cells can force Tregs to differentiate into IL-17-producing proinflammatory cells [45] . OX40 is also required for the accumulation of Tregs in the colon to prevent T-cellinduced colitis, and the lack of OX40 costimulation after Treg activation may lead to activation-induced cell death (AICD) [46 ] . An insight into these distinct effects on Tregs is gained from a recent study of OX40 in experimental autoimmune encephalomyelitis (EAE), in which the local cytokine milieu at the time of ligation was important: OX40 ligation early in the response (during antigen priming) expanded Tregs and reduced the severity of EAE and OX40 ligation later (when effector T cells had already infiltrated the central nervous system) caused an enhancement of effector T-cell responses and promoted the development of EAE [47] .
Tregs may not remain suppressive throughout their lifetime. In a recent study, it was demonstrated that some cells that lose FoxP3 develop an activated memory-type phenotype and are pathogenic in vivo [48 ] . The loss of FoxP3 appears linked to a proinflammatory microenvironment. Under such conditions, Tregs can acquire an effector T-cell phenotype, secreting IL-17 and interferon-g (IFN-g) [49, 50] , a phenomenon likely related to the ability of inflammatory cytokines such as IL-6 to methylate the FoxP3 TSDR site [21 ] . Furthermore, transfer of Tregs into lymphopenic mice has been shown to result in the loss of FoxP3 in up to 50% of adoptively transferred cells [51] , an important observation to consider if clinical Treg therapy is to be used in patients who are lymphopenic after immunosuppressive induction therapy.
In SOT, there is a trend for an increase in the number of FoxP3 þ cells in long-term operationally tolerant patients and, paradoxically, in patients undergoing acute rejection. For example, increased FOXP3 mRNA levels have been detected in rejecting cardiac [52] and renal allografts [53] , as well as in the urine of patients with rejecting renal transplants [54] . Higher peripheral FoxP3 þ cell numbers also predict a higher risk of development of cutaneous squamous cell carcinoma in renal transplant patients [55] . The increase in FoxP3 þ cells in acute rejection may be related to its upregulation on activated effector T cells, or an increase in Tregs in response to high donor-activated effector T-cell activity. Conversely, patients with renal transplants undergoing chronic rejection have lower numbers of peripheral FoxP3 þ cells compared with those with either normal graft function under immunosuppression or those who are operationally tolerant. The increase in FoxP3 þ cells in the graft and periphery is most striking in tolerant liver transplant recipients [56] [57] [58] [59] .
Experimental evidence for CD4R regulatory T-cell use in solid organ transplantation
Studies assessing the potential of nTregs, iTregs, and Tr1 cells to promote allograft survival in experimental transplantation have yielded promising results to date. We will now discuss some of these important studies.
Mouse regulatory T cells
Tregs may be generated in vivo or ex vivo for later adoptive transfer. In-vivo approaches are based on increasing the frequency or potency of Tregs by exposure to antigen, inducing an expansion of nTregs, or converting nonregulatory T cells to iTregs [60] . For example, Tregs may be generated in vivo by pretreating mice with a donor alloantigen (in the form of a donorspecific blood transfusion) along with a nondepleting anti-CD4 monoclonal antibody (mAb). Mice treated in this manner develop Tregs capable of preventing allograft rejection in vivo [61, 62] . Tregs isolated from these animals can also prevent allograft rejection in naive mice by cellular adoptive transfer. These Tregs display an increase in alpha-1,2-mannosidase expression, an enzyme involved in the synthesis and processing of Nlinked glycoproteins. The resultant altered N-glycosylation of Treg cell surface proteins has been shown to be necessary for Treg migration to lymph nodes where they can regulate priming [63] . Another method for in-vivo generation involves injection of IL-2-IL-2 mAb complexes into mice, resulting in an over 10-fold expansion of Tregs in vivo. Animals treated by this method are resistant to EAE induction and display tolerance to islet allografts [64 ] .
Tregs may be generated by similar principles in vitro, by culturing CD4 þ T cells with alloantigen and anti-CD4 antibody [65] . Tregs may also be generated in vitro by the conditioning of nonregulatory CD4 þ cells with alloantigen in the presence of IFN-g, which helps convert these cells into Tregs and induces preferential AICD in the non-Treg population [66, 67] . IFN-g-conditioned Tregs have been shown to prevent the rejection of skin and islet allografts in vivo [67] . Furthermore, these cells can inhibit transplant-associated vasculopathy [68 ] , a phenomenon current immunosuppressive drugs have failed to influence significantly. Interestingly, Tregs isolated from tolerant animals produce IFN-g transiently and rapidly after activation, which acts in an autocrine manner to activate the signal transducer and activator of transcription (STAT)-1 intracellular signaling pathway necessary for regulation [69] .
Human regulatory T cells
Human Tregs for therapy are generally produced by isolation of cells from peripheral or cord blood and subsequent ex-vivo expansion or direct use. In order to isolate Tregs efficiently and to a high purity, reliable markers of identification are required. Given the nonspecificity of CD25 and FoxP3 expression, a number of other markers have been explored. Of these markers, CD127 (the IL-7 receptor a-chain), CD49b (the a-chain of the integrin VLA-4 -a4b1), CD45RA, and the folate receptor 4 (FR4) are currently the most useful. Another surface marker, glycoprotein-A repetitions predominant (GARP or LRRC32), is linked to the expression of FoxP3 and associated with Treg suppressive activity, but its role in efficiently distinguishing Tregs requires further investigation [70] . Other Treg markers include CTLA-4, GITR, CD69, and CD44, but these are less useful as they may also be expressed in almost identical patterns on nonregulatory activated T cells.
The low expression of CD127 (CD127 lo ) correlates well with expression of FoxP3 and identifies Tregs that are highly suppressive in vivo [71] [72] [73] . In a recent study from our laboratory, CD25 þ CD127 lo Tregs were five-fold more effective at abrogating transplant arteriosclerosis in a humanized mouse model than Tregs selected on CD25 alone [74 ] . The absence of CD49b is another good marker for Tregs [75] . The benefit of CD127 and CD49b is that a population of Tregs can be isolated by negative selection alone without the need for CD25 positive selection.
CD45RA allows cells to be divided into CD25 þ CD45RA þ FoxP3 lo (resting naive Tregs), CD25 hi CD45RA -FoxP3 hi (activated Tregs), and CD25 þ CD45RA -FoxP3 lo (nonsuppressive T cells) populations [76 ] . Resting naive and activated Tregs are both suppressive in vitro, although only resting naive Tregs proliferate in vivo and evolve into suppressive CD45RA -Tregs. Umbilical cord blood (UCB) contains a high proportion of naive CD45RA þ cells and is, therefore, an attractive source of resting naive Tregs [77] . However, UCB Tregs are low in frequency and require either in-vitro culture or pooling of multiple units. Furthermore, UCB Tregs are 'third-party' (allogeneic to both the donor and recipient), although given the increase in the frequency of UCB banking in recent years, it may one day be possible to infuse autologous UCB Treg into a patient.
FR4 is constitutively expressed on the surface of Tregs and along with CD4 and CD25 identifies a population of Tregs that potently suppress allograft rejection [78] .
Ex-vivo expansion of isolated Tregs is generally performed by TCR stimulation with anti-CD3/anti-CD28 microbeads in the presence of recombinant human IL-2 [79 ,80] . The nonspecific TCR stimulation in this system leads to the production of a polyclonal population of Tregs. Another promising strategy for the production of human Tregs is based on lentivirus-mediated expression of FOXP3 in effector T cells, which results in stable and suppressive Treg populations [81] . Donor alloantigen-specific Tregs have been shown to be more potent suppressors in vitro and are theoretically safer for in-vivo use. Current methods for the production of antigenspecific Tregs include culture with allogeneic stimulators rather than anti-CD3/anti-CD28 microbeads [82, 83] , expansion of HLA-specific Tregs selected by tetramer [84] , and retroviral transduction of Tregs with genes that encode for TCRs with known antigen specificities.
Immunosuppression and regulatory T cells
Treg adoptive cellular therapy in SOT is likely to be initially introduced under the cover of conventional immunosuppression. In light of this, it is important to delineate the effects of immunosuppression on Treg activity and proliferation [85] . Tregs and effector T cells preferentially employ different intracellular activation pathways: Tregs utilize IL-2-dependent STAT-5 [86, 87] , whereas effector T cells utilize the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway [88] . Immunosuppression with rapamycin (an mTOR inhibitor) takes advantage of this distinction. The beneficial effects of rapamycin on Treg survival and proliferation have been demonstrated in vitro and in vivo [89] [90] [91] [92] [93] [94] . Alemtuzumab (a humanized anti-CD52 mAb used mainly for induction therapy) may also favor Treg survival, with evidence from one study demonstrating a higher proportional depletion of T-effector cells than Tregs [95] . Data in this study may be confounded by the introduction of rapamycin in patients early after transplantation. Indeed, in a separate study Treg numbers in alemtuzumab-treated patients remained low until the late introduction of rapamycin [96] .
There is no significant difference in circulating Treg numbers between renal transplant patients treated with belatacept (CTLA-4-Ig) in conjunction with basiliximab (chimeric anti-CD25 mAb) compared with patients treated with calcineurin inhibitors (CNIs) [97] . Nevertheless, CNIs such as cyclosporine have a detrimental effect on Tregs [98, 99] , complicating this observation. Interestingly, in this same study, patients receiving belatacept displayed higher levels of intragraft FoxP3 þ T cells during acute rejection [97] . The effects of anti-CD25 mAb on Tregs are not entirely clear. In the former study, basiliximab depleted all CD25-bearing cells, including Tregs. However, in another study examining daclizumab (a humanized anti-CD25 mAb) in cardiac transplant patients, Treg generation in the periphery was not affected [100] . Despite the detrimental effects of CNIs on Tregs, in a study examining topical CNIs for atopic dermatitis using tacrolimus, there was a significant reduction in intralesional CD25 þ but not FoxP3 þ cells [101] .
In a recent study investigating a novel CD28 antagonist, there was an increase in the number and activity of Tregs in a nonhuman primate renal transplantation model [102 ] . This costimulatory blockade, unlike CTLA-4-Ig, does not affect physiological CD80/86-CTLA-4 interaction, therefore allowing normal immune regulation through this important pathway to continue [37] .
Clinical trials
At the time of writing, there are no ongoing clinical trials testing the efficacy of Tregs in SOT. There have, however, been several studies investigating Tregs for the treatment of graft-versus-host disease (GVHD) posthematopoeitic stem cell transplantation (HSCT). It is important to take note of these studies as they are paving the way for Treg therapy in SOT. Trzonkowski et al. [79 ] have reported the use of ex vivo expanded recipient-derived Tregs in two patients: in one case of chronic GVHD, there was significant alleviation of the symptoms and a reduction in required immunosuppression, whereas in one case of severe grade IV acute GVHD, there was only a transient improvement in symptoms and signs. 
Conclusion
Over the past decade, there have been great advances in our overall understanding of Treg biology, and we are closer than ever to the first clinical trials in SOT. As a stepping stone to these trials, humanized mouse in-vivo models are proving invaluable. These models provide important efficacy data, as well as limited safety data. However, when considering Treg therapy in SOT, it is important to keep in mind the excellent short-term outcomes with conventional immunosuppression. The beneficial effects of Treg therapy in the majority of cases are envisaged to be in the long term. In order to evaluate Treg therapy in the short term, trials will need to be performed in situations in which acute rejection rates are high and conventional immunosuppression is risky, such as intestinal or composite tissue transplantation. In these cases, Treg cellular therapy may be given in the first instance as an adjunct together with reduced-dose immunosuppression, in an attempt to achieve prope tolerance. Whether Tregs will eventually emerge as a toleranceinducing monotherapy is yet to be revealed.
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